47
Participants
Start Date
April 30, 2007
Primary Completion Date
June 30, 2008
Study Completion Date
August 31, 2010
Radiation Therapy
2 Gy/fraction, single daily fractions M-F, to 60 Gy total
Temozolomide
"In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles"
Sorafenib
In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
Center for Cancer and Blood Disorders, Bethesda
Virginia Cancer Institute, Richmond
Spartanburg Regional Medical Center, Spartanburg
Northeast Georgia Medical Center, Gainesville
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, Nashville
Oncology Hematology Care, Cincinnati
Grand Rapids Clinical Oncology Program, Grand Rapids
Methodist Cancer Center, Omaha
South Texas Oncology and Hematology, San Antonio
Collaborators (1)
Bayer
INDUSTRY
SCRI Development Innovations, LLC
OTHER